Treatment
Effectiveness of Surgical Treatment on Survival of Patients with Malignant Pleural Mesothelioma
Cancers 2025 July 16 [Link] Renata Báez-Saldaña, María Esther Marmolejo-Torres, Marco Antonio Iñiguez-García, Aída Jiménez-Corona, Juan Alberto Berrios-Mejía Abstract Background: The benefit of surgery for malignant pleural mesothelioma is highly debated, as few robust clinical trials show its effectiveness. Objective: To examine the long-term survival of patients with malignant pleural mesothelioma who underwent surgical treatment…
Read MoreTowards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Critical Reviews in Oncology/Hematology 2025 July 23 [Link] Paolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, Piergiorgio Solli, Mario Occhipinti Abstract Pleural mesothelioma is a rare malignancy that has historically had a poor prognosis, even with systemic chemotherapy. Although immune checkpoint inhibitors have improved survival rates for patients with advanced, unresectable disease, their role in perioperative…
Read MoreEnhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report
Molecular and Clinical Oncology 2025 July 3 [Link] Kazuki Yamada, Takehiro Uemura, Aya Mukai, Tatsuya Tanaka, Ippei Sakakibara, Keima Ito, Yuta Mori, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Tomoko Tajiri, Yutaka Ito, Tetsuya Oguri, Akio Niimi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer with limited treatment options and poor prognosis.…
Read MoreNeoadjuvant immunotherapy in a solitary, isolated peritoneal mesothelioma involving the abdominal wall: a case report
Immunotherapy 2025 July [Link] Parsa Charkhchi, Ryan Le, Taryn E Cazzolli, Raina R Flores, Roberto A Martinez, Supreet Kaur, Mio Kitano Abstract Mesothelioma is a rare neoplasm with a minority of cases originating from the peritoneum. Patients are generally treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and various systemic therapies. In recent…
Read MoreLong Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis
Cureus 2025 June 13 [Link] Thejas Swaroop Konduru, Gourav Gourisaria, Goksu Ozen, Pradeep Karunakaran Thozhuthumparambil Abstract Peritoneal mesothelioma is a rare and aggressive malignancy that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like asbestos…
Read MoreThe Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Cancers 2025 June 25 [Link] Yuliya Semenova, Zhandos Burkitbayev, Nurtas Kalibekov, Alexandr Digay, Bakhyt Zhaxybayev, Oxana Shatkovskaya, Saule Khamzina, Dinara Zharlyganova, Zhuldyz Kuanysh, Almira Manatova Abstract Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
The Annals of Thoracic Surgery 2025 June 28 [Link] Peter L Zhan, Maureen E Canavan, Justin M Bader, Daniel J Boffa, Benjamin J Resio, Gavitt A Woodard Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS 2) trial demonstrated no survival benefit from cytoreductive surgical resection over chemotherapy alone in resectable pleural mesothelioma. Using the…
Read MoreLong term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma
Lung Cancer 2025 August [Link] Vishruta Dumane, Juliana Runnels, Raja Flores, Andrea Wolf, Weijia Fu, Madhu Mazumdar, Thomas Marron, Jorge Gomez, Kenneth Rosenzweig Abstract Purpose: Lung-sparing pleurectomy/decortication (P/D) is the primary surgical approach for malignant pleural mesothelioma (MPM), and combining it with other therapies enhances patient outcomes.This report presents the extended follow-up results of MPM…
Read MoreClinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations
Journal of Thoracic Oncology 2025 June 27 [Link] Michele Carbone, Michael Minaai, Muaiad Kittaneh, Thomas Krausz, Markku M Miettinen, Qiang Pan Hammarström, Lennart Hammarström, Hassan Abolhassani, Ian Pagano, Ronghui Xu, Flavia Novelli, Giovanni Gaudino, Sandra Pastorino, Kavita Y Sarin, Robert T Ripley, Harvey I Pass, David S Schrump , Haining Yang Abstract Introduction: Mesothelioma is…
Read More